AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

NASDAQ:AMRX • US03168L1052

13.5 USD
-0.31 (-2.24%)
Last: Mar 2, 2026, 11:42 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to AMRX. AMRX was compared to 193 industry peers in the Pharmaceuticals industry. AMRX has an average financial health and profitability rating. AMRX is valued quite cheap, but it does not seem to be growing. These ratings could make AMRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • AMRX had positive earnings in the past year.
  • AMRX had a positive operating cash flow in the past year.
  • In the past 5 years AMRX reported 4 times negative net income.
  • Of the past 5 years AMRX 4 years had a positive operating cash flow.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • AMRX has a Return On Assets of 0.16%. This is in the better half of the industry: AMRX outperforms 78.76% of its industry peers.
  • AMRX has a better Return On Invested Capital (10.43%) than 90.16% of its industry peers.
  • AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is below the industry average of 12.93%.
  • The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(10.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROIC 10.43%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

  • AMRX's Profit Margin of 0.20% is fine compared to the rest of the industry. AMRX outperforms 78.76% of its industry peers.
  • With an excellent Operating Margin value of 12.32%, AMRX belongs to the best of the industry, outperforming 85.49% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AMRX has grown nicely.
  • AMRX has a Gross Margin of 36.76%. This is in the better half of the industry: AMRX outperforms 60.62% of its industry peers.
  • In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
  • AMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • AMRX has an Altman-Z score of 1.95. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of AMRX (1.95) is better than 63.21% of its industry peers.
  • The Debt to FCF ratio of AMRX is 11.13, which is on the high side as it means it would take AMRX, 11.13 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 11.13, AMRX belongs to the best of the industry, outperforming 80.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Altman-Z 1.95
ROIC/WACC1.02
WACC10.18%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

  • AMRX has a Current Ratio of 2.13. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AMRX (2.13) is comparable to the rest of the industry.
  • AMRX has a Quick Ratio of 1.42. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.42, AMRX is doing worse than 64.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.13
Quick Ratio 1.42
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.83%, which is quite impressive.
  • Measured over the past 5 years, AMRX shows a small growth in Earnings Per Share. The EPS has been growing by 5.92% on average per year.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.47%

3.2 Future

  • Based on estimates for the next years, AMRX will show a small growth in Earnings Per Share. The EPS will grow by 5.77% on average per year.
  • Based on estimates for the next years, AMRX will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
EPS Next Y13.73%
EPS Next 2Y18.68%
EPS Next 3Y3.76%
EPS Next 5Y5.77%
Revenue Next Year6.51%
Revenue Next 2Y7.39%
Revenue Next 3Y-2.76%
Revenue Next 5Y-0.47%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.07, AMRX is valued correctly.
  • AMRX's Price/Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 87.05% of the companies in the same industry.
  • AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.07.
  • The Price/Forward Earnings ratio is 14.13, which indicates a correct valuation of AMRX.
  • AMRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMRX is cheaper than 84.97% of the companies in the same industry.
  • AMRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.07
Fwd PE 14.13
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 88.08% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 87.05% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 17.94
EV/EBITDA 11.25
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • AMRX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AMRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.17
PEG (5Y)2.71
EPS Next 2Y18.68%
EPS Next 3Y3.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (3/2/2026, 11:42:47 AM)

13.5

-0.31 (-2.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners45.17%
Inst Owner Change-0.48%
Ins Owners46.29%
Ins Owner Change-0.21%
Market Cap4.24B
Revenue(TTM)N/A
Net Income(TTM)5.90M
Analysts81.82
Price Target14.79 (9.56%)
Short Float %8.12%
Short Ratio4.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.63%
Min EPS beat(2)21.21%
Max EPS beat(2)40.06%
EPS beat(4)3
Avg EPS beat(4)19.7%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)26.2%
EPS beat(12)11
Avg EPS beat(12)30.21%
EPS beat(16)11
Avg EPS beat(16)19.73%
Revenue beat(2)0
Avg Revenue beat(2)-2.51%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)-0.41%
Revenue beat(4)1
Avg Revenue beat(4)-2.13%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)3
Avg Revenue beat(8)-0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.45%
Revenue beat(16)8
Avg Revenue beat(16)-0.15%
PT rev (1m)0%
PT rev (3m)8.75%
EPS NQ rev (1m)2.21%
EPS NQ rev (3m)2.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE 16.07
Fwd PE 14.13
P/S 1.45
P/FCF 17.94
P/OCF 12.95
P/B N/A
P/tB N/A
EV/EBITDA 11.25
EPS(TTM)0.84
EY6.22%
EPS(NY)0.96
Fwd EY7.08%
FCF(TTM)0.75
FCFY5.57%
OCF(TTM)1.04
OCFY7.72%
SpS9.34
BVpS-0.35
TBVpS-4.11
PEG (NY)1.17
PEG (5Y)2.71
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.16%
ROE N/A
ROCE 13.2%
ROIC 10.43%
ROICexc 11.26%
ROICexgc 21.11%
OM 12.32%
PM (TTM) 0.2%
GM 36.76%
FCFM 8.06%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexgc growth 3Y25.12%
ROICexgc growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 11.13
Debt/EBITDA 4.36
Cap/Depr 37.95%
Cap/Sales 3.11%
Interest Coverage 1.67
Cash Conversion 54.45%
Profit Quality 4008.53%
Current Ratio 2.13
Quick Ratio 1.42
Altman-Z 1.95
F-Score7
WACC10.18%
ROIC/WACC1.02
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y13.73%
EPS Next 2Y18.68%
EPS Next 3Y3.76%
EPS Next 5Y5.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.47%
Revenue Next Year6.51%
Revenue Next 2Y7.39%
Revenue Next 3Y-2.76%
Revenue Next 5Y-0.47%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.39%
EBIT Next 3Y9.98%
EBIT Next 5Y3.87%
FCF growth 1Y72%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y75.78%
OCF growth 3Y6.86%
OCF growth 5Y180.48%

AMNEAL PHARMACEUTICALS INC / AMRX FAQ

What is the fundamental rating for AMRX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AMRX.


What is the valuation status for AMRX stock?

ChartMill assigns a valuation rating of 7 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.


How profitable is AMNEAL PHARMACEUTICALS INC (AMRX) stock?

AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 6 / 10.


How financially healthy is AMNEAL PHARMACEUTICALS INC?

The financial health rating of AMNEAL PHARMACEUTICALS INC (AMRX) is 5 / 10.


Can you provide the expected EPS growth for AMRX stock?

The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 13.73% in the next year.